Asset profile
Sacituzumab Govitecan
Antibody–drug conjugate
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
122 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sacituzumab Govitecan: this drug | Approved | Antibody–drug conjugate | TROP2 | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | ||
| DB-1305 | Phase 2 | Antibody–drug conjugate | TROP2 | ||
| BL-M02D1 | Phase 1/2 | Antibody–drug conjugate | TROP2 | ||
| LCB84 | Phase 1/2 | Antibody–drug conjugate | TROP2 | ||
| MT-302 | Phase 1 | Small molecule | TROP2 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 107 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(92 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (18)
November 2026 (3)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-11 · NCT06329869 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-01 · NCT06401824 · CT.gov ↗
What to watch
Phase 2Ovarian CarcinomaActive not recruiting
Est. primary completion 2026-11-01 · NCT06028932 · CT.gov ↗
What to watch
December 2026 (15)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
Phase 1Gastrointestinal CancerRecruiting
Est. primary completion 2026-12 · NCT06065371 · CT.gov ↗
What to watch
Phase 1Advanced or Metastatic Solid Tumor, Liver FailureRecruiting
Est. primary completion 2026-12 · NCT04617522 · CT.gov ↗
What to watch
Phase 1Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05833867 · CT.gov ↗
What to watch
Phase 2Endometrial CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04251416 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT04639986 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12-01 · NCT05838521 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Muscle-invasive Bladder CancerRecruiting
Est. primary completion 2026-12-01 · NCT06682728 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNARecruiting
Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗
What to watch
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07359404 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05675579 · CT.gov ↗
What to watch
Phase 2Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT06528483 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Resectable Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07492914 · CT.gov ↗
What to watch
2027 (36)
January 2027 (7)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT06827613 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01 · NCT04039230 · CT.gov ↗
What to watch
Phase 1Solid TumorActive not recruiting
Est. primary completion 2027-01-07 · NCT04794699 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal MetastasesRecruiting
Est. primary completion 2027-01-15 · NCT06462092 · CT.gov ↗
What to watch
Phase 2Brain MetastasisNot yet recruiting
Est. primary completion 2027-01-15 · NCT06462079 · CT.gov ↗
What to watch
Phase 2Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer …Active not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
February 2027 (7)
Phase 1/2Breast Cancer, Triple Negative Breast CancerRecruiting
Est. primary completion 2027-02 · NCT06238921 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT06612203 · CT.gov ↗
What to watch
Phase 2Muscle-invasive Urothelial Carcinoma of the BladderActive not recruiting
Est. primary completion 2027-02 · NCT05535218 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2027-02 · NCT04559230 · CT.gov ↗
What to watch
Phase 3Triple Negative Breast Cancer, PD-L1 PositiveActive not recruiting
Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗
What to watch
Phase 1/2Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder CancerRecruiting
Est. primary completion 2027-02-01 · NCT04724018 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03 · NCT05186974 · CT.gov ↗
What to watch
Early phase / not applicableTNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT07046455 · CT.gov ↗
What to watch
Phase 3HER2-negative Breast Cancer, Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-03-30 · NCT04595565 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-05 · NCT05101096 · CT.gov ↗
What to watch
Phase 2Thymoma, Thymic CarcinomaRecruiting
Est. primary completion 2027-05 · NCT06248515 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-01 · NCT06665178 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07367178 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2027-06 · NCT07040644 · CT.gov ↗
What to watch
Phase 3Triple Negative Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal CarcinomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT07674615 · CT.gov ↗
What to watch
Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06878625 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06616987 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast CancerNot yet recruiting
Est. primary completion 2027-08 · NCT07299409 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06667167 · CT.gov ↗
What to watch
Phase 2Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder …Recruiting
Est. primary completion 2027-11-01 · NCT06161532 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Differentiated Thyroid Cancer, Anaplastic Thyroid CancerRecruiting
Est. primary completion 2027-12 · NCT06235216 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04647916 · CT.gov ↗
What to watch
2028 (19)
January 2028 (2)
Phase 2Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer …Recruiting
Est. primary completion 2028-01-02 · NCT07063212 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
March 2028 (2)
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04 · NCT05840211 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2028-05-31 · NCT07788222 · CT.gov ↗
What to watch
June 2028 (3)
Phase 1/2Triple Negative Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06926920 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06263543 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
July 2028 (3)
Phase 3Triple Negative Breast Cancer, PD-L1 NegativeActive not recruiting
Est. primary completion 2028-07 · NCT05382299 · CT.gov ↗
What to watch
Phase 1/2Metastatic Triple-Negative Breast CancerRecruiting
Est. primary completion 2028-07-01 · NCT07011654 · CT.gov ↗
What to watch
Phase 2Gland, Salivary Gland CancersRecruiting
Est. primary completion 2028-07-31 · NCT05884320 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2028-08-01 · NCT05770531 · CT.gov ↗
What to watch
Phase 2/3Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-08-01 · NCT06243393 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC)Not yet recruiting
Est. primary completion 2028-08-31 · NCT07778368 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-09 · NCT06167317 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast CancerRecruiting
Est. primary completion 2028-10 · NCT04230109 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Not yet recruiting
Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Lung CancerActive not recruiting
Est. primary completion 2028-12-30 · NCT06055465 · CT.gov ↗
What to watch
2029 (8)
February 2029 (1)
Phase 2Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-02-01 · NCT07339059 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma …Recruiting
Est. primary completion 2029-04-12 · NCT07504588 · CT.gov ↗
What to watch
June 2029 (2)
September 2029 (2)
October 2029 (2)
Phase 2Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗
What to watch
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-10 · NCT06801834 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 2Urothelial Bladder CarcinomaActive not recruiting
Est. primary completion 2030-01 · NCT06133517 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
April 2030 (2)
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 2TNBC, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2030-12-14 · NCT07271992 · CT.gov ↗
What to watch
Phase 3Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial CarcinomaRecruiting
Est. primary completion 2030-12-31 · NCT06524544 · CT.gov ↗
What to watch
2031 (2)
2033 (1)
March 2033 (1)
Phase 3Breast Cancer, Triple-negative Breast CancerNot yet recruiting
Est. primary completion 2033-03-31 · NCT07178730 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.